Enzon Pharmaceuticals (ENZN) Suspends Clinical Development, To Explore a Sale

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced that its Board of Directors has retained Lazard to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets, or a sale of the Company.

Based on clinical data on the androgen receptor program, Enzon plans to suspend clinical development with a goal to conserve capital and maximize value returned to shareholders. A special committee of Enzon's Board of Directors was established to oversee the review. There can be no assurance that the review will result in the consummation of any transaction.

Alex Denner, Chairman of the Board, commented: "The Board of Directors, following a review of the Company's assets and strategic direction, has determined that it is in the best interest of Enzon's shareholders to pursue a sale, in whole or in part, of the Company. In addition to a strong balance sheet and royalty revenues, Enzon's drug candidates and technologies offer the potential for a variety of transactions."

(shares halted)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lulus forms special committee to review strategic alternatives
• Baker Hughes wins conditional EU approval for $13.6 billion Chart deal
• Paramount defends Skydance-WBD merger amid state AG lawsuit